Adaptive clinical trial design: has its time come?
Nelson
Nancy J
NJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000592:standards*; D019938:Cyclin D1 / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D009154:Mutation; D009369:Neoplasms / Q000378:metabolism / Q000628:therapy*; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D048493:Proto-Oncogene Proteins B-raf / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras); D012107:Research Design / Q000592:standards*; D047488:Retinoid X Receptors / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D018631:ras Proteins / Q000378:metabolism
D014408:Biomarkers, Tumor; C530104:CCND1 protein, human; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D047488:Retinoid X Receptors; D042461:Vascular Endothelial Growth Factor A; D019938:Cyclin D1; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins